The problem — Pathology models trained on TCGA-scale data (~10,000 WSIs) generalise poorly across tissue types, staining protocols, and scanning hardware. A model that achieves excellent AUROC on a benchmark cohort frequently degrades when moved to a different site's scanner — not because the biology changed, but because the feature distribution did.
What it is / how it works — UNI is a Vision Transformer-Large (ViT-L/16) encoder trained with the DINOv2 self-supervised recipe on Mass-100K: 100 million+ patches drawn from 100,402 H&E whole-slide images spanning 20 tissue types (77 TB of data, sourced from Massachusetts General Hospital, Brigham and Women's Hospital, and GTEx). No labels are used during pretraining — the encoder learns patch representations purely from structure and scale variation. At inference, UNI converts a cropped tissue patch into a 1024-dimensional embedding; slide-level tasks stack these via attention-based multiple instance learning (ABMIL). Evaluated across 34 clinical tasks, UNI demonstrated state-of-the-art results on ROI classification, subtype prediction (108-class OncoTree), and CAMELYON16 tumour detection (AUROC 0.966), validating the scaling thesis: more data diversity compounds into generalist representations in ways that narrow domain pretraining cannot match.
Where it fits in the pipeline — UNI operates at the features stage of a digital-pathology pipeline, downstream of tiling and QC and upstream of slide-level aggregation and readout. It is not a classifier; it is a feature extractor. As Foundation Models Are Not Pipelines argues, the encoder is the smallest component of a deployable system — tiling strategy, stain normalisation choice, aggregation head, calibration, and provenance logging each contribute independent failure modes that the embedding quality cannot compensate for. The self-supervised embedding paradigm it exemplifies is the same across modalities: frozen encoder, task-specific head, minimal labelled data.
Where it breaks — Mass-100K is proprietary; independent reproduction of the pretraining is not feasible, which raises reproducibility questions for regulated applications. The benchmark suite draws heavily from TCGA, creating contamination risk when evaluating on TCGA-derived splits. License (CC-BY-NC-ND 4.0) prohibits commercial deployment without prior approval. Resolution-agnostic claims hold within the training distribution of H&E; application to IHC, multiplex IF, or FISH panels requires domain-adaptation validation before any clinical conclusion.